Tous Actualités
Suivre
Abonner Isotechnika Inc.

Isotechnika Inc.

Isotechnika Announces Nine Month Safety Data From the Phase III Psoriasis Trial for ISA247

Edmonton, Canada (ots/PRNewswire)

Isotechnika Inc. (TSX:ISA)
announced today nine month interim safety and efficacy data obtained
from its 24 week Phase III psoriasis trial and 12 week extension for
its lead immunosuppressive drug, ISA247.
Patients completing the 24 week Canadian Phase III SPIRIT trial
were given the opportunity to continue therapy for an additional 36
weeks or to discontinue therapy. Ninety percent of patients who
completed the trial chose to enroll in the extension trial. Those
patients who chose to enroll in the extension trial were moved from
the 0.2 mg/kg (low dose) or 0.4 mg/kg (high dose) bid dose groups
into the 0.3 mg/kg bid (mid dose group). Patients who commenced the
SPIRIT trial in the 0.3 mg/kg bid dose group remained on the same
dosage regimen for the duration of the extension trial. The goals of
the extension trial are to demonstrate continued therapeutic benefit
to psoriasis patients and to gather longer term safety and efficacy
data.
To date, 254 patients have completed 12 weeks of the extension
trial for a total 36 weeks of treatment. The data indicates that
there are no clinically or statistically significant changes in serum
creatinine or glomerular filtration rate (GFR) over the duration of
the trial period.
As anticipated, the improvement in PASI scores remained fairly
stable for those patients previously in the mid dose group of the
SPIRIT trial. Patients previously in the low dose group have seen an
improvement in mean percent change in PASI scores from 42% to 66%
after 12 weeks on the mid dose. Patients previously in the high dose
group have seen a slight change in PASI scores from 70% to 61%.
"Our optimism regarding the efficacy of ISA247 and lack of renal
or any other toxicity seen after 24 weeks of therapy is confirmed in
the extension study data to date," stated Dr. Gilles Lauzon, Director
of the Division of Dermatology at the University of Alberta.
"I am extremely pleased that the nine month data strongly suggests
long term safety of ISA247 in patients suffering from moderate to
severe psoriasis," added Dr. Randall Yatscoff, Isotechnika's
President & CEO. "The data generated to date continues to support the
safety and efficacy profile of ISA247. In addition, the Company
reached a significant milestone with ISA247 treatment. Beginning on
December 2, 2005, a number of psoriasis patients have received
continuous oral treatment of ISA247 for one year. We look forward to
receiving data on these patients in the coming months."
Management will host a conference call to provide an overview of
the nine month interim safety data this afternoon at 4:15 p.m. EST /
2:15 p.m. MST. All Interested parties can access the live conference
call (listen only mode) by accessing
http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=1326820 or
through the home page of the Company's corporate Web site at
www.isotechnika.com. The conference call will be archived for 90 days
through the web cast archives at www.newswire.ca.
About Isotechnika
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant
currently in an extension protocol of a Canadian Phase III human
clinical trial for the treatment of moderate to severe psoriasis. In
addition, ISA247 has successfully completed a Phase IIa trial for
kidney transplantation. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93 which is in
Phase I.
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(R) breath kit. The
Helikit(R), a 13C urea breath test, is used for the detection of H.
pylori, a bacterium that infects a large portion of the population.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
Partnerships
Isotechnika Inc. has a collaboration agreement with Hoffman La
Roche which licensed the worldwide rights to develop and
commercialize Isotechnika's novel molecule ISA247 for all transplant
indications. In addition, the Company has an exclusive worldwide
licensing agreement with Atrium Medical Corporation for the use of
ISA247 and TAFA93 specifically with drug eluting devices for the
non-systemic treatment of vascular, cardiovascular, target vessel and
tissue disorders.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

Contact:

For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., +1-(780)-487-1600-(246), +1-(780)-484-4105 (fax),
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., +1-(780)-909-4661,
+1-780-484-4105 (fax), sgillis-paulgaard@isotechnika.com; To request
a free copy of this organization's annual report, please go to
http://www.newswire.ca and click on Tools for Investors.

Plus de actualités: Isotechnika Inc.
Plus de actualités: Isotechnika Inc.
  • 16.11.2005 – 15:35

    Isotechnika Announces Change in Executive Management

    Edmonton, Canada, November 16 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA), a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics, announced today that effective immediately, Joseph Koziak, who served as Executive Vice President is no longer an officer of the company. About Isotechnika Isotechnika Inc. is an international biopharmaceutical ...

  • 07.11.2005 – 13:10

    Isotechnika's Phase III Psoriasis Spirit Trial Achieves Safety and Efficacy Endpoints

    Edmonton, Canada, November 7 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A summary of the results is as follows: - All primary and secondary efficacy endpoints were achieved at 24 weeks - Efficacy endpoints were ...

  • 04.11.2005 – 23:28

    Media Advisory - Isotechnika to Announce Phase III Psoriasis Spirit Trial Results

    Edmonton, Canada, November 4 (ots/PRNewswire) - - ATTN: Business/Assignment Editors: EDMONTON, Canada, November 4 /PRNewswire/ -- Isotechnika Inc. will announce the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247 on Monday, November 7th at 7:00 a.m. EST/5:00a.m. MST. Management will ...